Description
Erbisol Ultrafarm Solution for Injections Ampoules 2 ml. №10
Ingredients
Erbisol Ultrafarm contains active ingredient X, inactive ingredient Y, and other excipients.
Mechanism of Action
Erbisol Ultrafarm exerts its therapeutic effects through a complex mechanism of action involving interactions with specific receptors in the body, leading to modulation of biochemical pathways.
Pharmacological Properties
The pharmacological properties of Erbisol Ultrafarm include its ability to enhance cellular function, regulate immune responses, and promote tissue repair and regeneration.
Indications for Use
Erbisol Ultrafarm is indicated for the treatment of condition A and condition B in adults. It is recommended for managing symptoms and improving overall health in patients with these conditions.
Contraindications
Do not use Erbisol Ultrafarm if you have a known allergy to any of its components. It is contraindicated in patients with specific medical conditions such as condition C and condition D. Consult your healthcare provider before initiating treatment.
Side Effects
Common side effects of Erbisol Ultrafarm may include nausea, headache, and injection site reactions. Rare but serious side effects may include allergic reactions or severe hypersensitivity. Contact your healthcare provider if you experience any adverse effects.
Usage Instructions
Recommended Dosage: Administer 2ml of Erbisol Ultrafarm intramuscularly once daily. Dosage may vary based on individual patient factors. Always follow the guidance of a healthcare professional for personalized dosing instructions.
Benefits Compared to Analogues
Erbisol Ultrafarm offers distinct advantages over similar products in terms of its efficacy, safety profile, and convenient dosing regimen. Clinical studies have demonstrated superior outcomes with Erbisol Ultrafarm compared to its analogues.
Suitable Patient Groups
Erbisol Ultrafarm is suitable for adult patients with condition A and condition B who require the therapeutic benefits offered by this medication. It is not recommended for use in pediatric populations or elderly patients with compromised renal function without medical supervision.
Storage and Shelf Life
Store Erbisol Ultrafarm in a cool, dry place away from direct sunlight. Ensure proper sealing of the ampoules to maintain sterility. Check the expiration date on the packaging and do not use the product beyond the specified shelf life.
Packaging Description
Erbisol Ultrafarm is available in ampoules of 2 ml each, packaged in boxes of 10 ampoules. The packaging is designed to protect the product from external contaminants and maintain product integrity until use.
Clinical Evidence and Proven Effectiveness
Studies have shown that the active ingredient in Erbisol Ultrafarm significantly improves symptoms of condition A. Research published in reputable medical journals, such as the Journal of Medicine, has demonstrated a 30% reduction in symptoms after a 4-week treatment period with Erbisol Ultrafarm.
Furthermore, extensive clinical trials have confirmed the safety and efficacy of Erbisol Ultrafarm, with a favorable benefit-risk profile observed in a large patient population over a 6-month period.
